Quinoline-4-ylcyclohexane compounds of IDO inhibitor

Abstract

The present invention relates to a class of quinoline-4-ylcyclohexane compounds, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof, and a preparation method thereof, and separate uses of the compounds or combined uses of the compounds and other drugs in treatment of diseases having the pathological features of IDO-mediated tryptophan metabolism pathway.

Description

technical field [0001] The present invention relates to a class of quinolin-4-ylcyclohexane compounds, their pharmaceutically acceptable salts, hydrates, solvates or stereoisomers, their preparation methods and the compounds alone or in combination with other drugs It is used in the treatment of diseases with pathological features of IDO-mediated tryptophan metabolic pathway. Background technique [0002] Tryptophan is an essential amino acid for the human body. Part of the tryptophan obtained from the diet is used to synthesize protein and the neurotransmitter serotonin, and the rest is mainly metabolized through the kynurenine pathway. Indoleamine 2,3-dioxygenase 1 (IDO1) is the rate-limiting enzyme that catalyzes the metabolism of tryptophan along the kynurenine pathway. When the expression level of IDO1 is high in tissue cells, a large amount of tryptophan is metabolized through the kynurenine metabolic pathway, and the content of tryptophan decreases, which directly i...

AI Technical Summary

Problems solved by technology

[0004] A large number of experimental data show that IDO inhibitors have therapeutic and preventive effects in various diseases such as tumors, and have good application prospects. However, existing IDO inhibitors have shown insufficient effectiveness or dose-limiting toxicity in clinical trials. Development of novel IDO inhibitors

Images